Loading...
HSChapter 30
U.S. exports of immunological products, unmixed, not put up in measured doses (HS 300213) totaled $38.8M in July 2026.
Immunological Products, Unmixed, Not Put Up in Measured Doses imports of $5.8M in July 2026 ran 66% below the year-to-date monthly average of $16.8M.
Last updated: July 2026 dataMonoclonal antibodies and other unmixed immunological products not packaged for retail sale represent some of the highest-value pharmaceutical trade flows in the global biologics market, serving as bulk intermediates for finished biologic drug manufacturing. The US schedule provides a dedicated line for monoclonal antibodies (3002130010) alongside a broader immunological products line (3002130090), with a legacy undifferentiated line (3002130000) also present. Germany and Switzerland lead US imports under this heading, reflecting the concentration of major biopharmaceutical manufacturers and contract development organizations in those countries, with the United Kingdom and China also significant sources. Admissibility is complex; importers should consult a licensed customs broker and confirm FDA CBER or CDER authorization requirements applicable to the specific product.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
129 shipments/mo
These conditions define the boundary between bulk pharmaceutical intermediates (heading 300213) and finished or formulated biologics (heading 300215 or 300290). An immunological product that has been mixed with excipients, adjuvants, or other active substances, or that has been packaged in unit doses for retail or clinical use, would generally fall outside 300213 and require reclassification. Correct classification depends on the product's formulation state and packaging at the time of importation.
Bulk monoclonal antibodies imported as drug substances are subject to FDA oversight under either CDER (for therapeutic mAbs) or CBER (for certain diagnostic or blood-related mAbs), and the foreign manufacturing facility must hold an appropriate FDA establishment registration. Importers should also confirm whether the specific product requires an Investigational New Drug (IND) authorization or a Biologics License Application (BLA) before commercial importation is permissible.
HS10 import codes under this HS6 parent, each with its own page. Source: U.S. Harmonized Tariff Schedule.
| Code | Description | Import Value | Effective Tariff % | Dutiable Share | Duty Collected |
|---|---|---|---|---|---|
| 3002130010 | Monoclonal Antibodies, Unmixed, Not Retail Sale | $4.0M | 0.05% | 0.50% | $2K |
| 3002130090 | Immunological Products, Unmixed, Not Retail Sale | $1.7M | 0.00% | 0.00% | -- |
HS10 export codes under this HS6 parent, each with its own page. Source: U.S. Schedule B export classification.
| Code | Description | Export Value |
|---|---|---|
| 3002130000 | Immunological Products,not Mixed not Retail Sale | $38.8M |
Import lines come from the U.S. Harmonized Tariff Schedule and export lines from Schedule B. The two are numbered by different agencies, so the same 10-digit code can appear in both tables describing a different product.
Supplier Network
Get discovered by U.S. importers searching for HS 300213 — Immunological Products, Unmixed, Not Put Up in Measured Doses. Be the first supplier listed.
ImportsExports
Imports
$5.8MYoY · Pro
Exports
$38.8MYoY · Pro
12-mo low · imports
YoY · ProThrough July 2026. Source: U.S. Census Bureau.
Exports · July 2026
destination
Austria and Netherlands together take 50% of it.
customs district
origin
entry
rate provision · imports
99.7% enters free of duty; the effective duty rate is 0.04%.